Scheduled injection of ramosetron for prevention of nausea and vomiting following single-port access total laparoscopic hysterectomy: a prospective randomized study.

Autor:	Li SC; Department of Obstetrics and Gynecology, Yonsei University Wonju College of Medicine, Wonju, Korea., Wang Y; Department of Obstetrics and Gynecology, Yonsei University Wonju College of Medicine, Wonju, Korea., Choi SJ; Department of Obstetrics and Gynecology, Yonsei University Wonju College of Medicine, Wonju, Korea., Jung YS; Department of Obstetrics and Gynecology, Yonsei University Wonju College of Medicine, Wonju, Korea., Han KH; Department of Obstetrics and Gynecology, Yonsei University Wonju College of Medicine, Wonju, Korea., Chung IB; Department of Obstetrics and Gynecology, Yonsei University Wonju College of Medicine, Wonju, Korea., Lee SH; Department of Obstetrics and Gynecology, Yonsei University Wonju College of Medicine, Wonju, Korea.; Department of Obstetrics and Gynecology, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
Jazyk:	angličtina
Zdroj:	Obstetrics & gynecology science [Obstet Gynecol Sci] 2019 Sep; Vol. 62 (5), pp. 344-351. Date of Electronic Publication: 2019 Jul 23.
DOI:	10.5468/ogs.2019.62.5.344
Abstrakt:	Objective: The purpose of this study was to evaluate the effectiveness of scheduled ramosetron injections for controlling postoperative nausea and vomiting (PONV) after single-port access total laparoscopic hysterectomy (SPA-TLH). Methods: Ninety patients who underwent SPA-TLH at the Korean National Health Insurance Service Ilsan Hospital between June 2013 and July 2014 were enrolled in this prospective, randomized, double-blinded, placebo-controlled study. The patients were divided into 2 groups as follows: the ramosetron group (0.3 mg intravenously [IV]; n=45) and the placebo group (normal saline IV; n=45). Both groups received their respective injections 12 and 24 hours post surgery. The incidence and severity of PONV (numerical rating scale, 0-10), and the use of rescue antiemetics post surgery were evaluated. Results: Demographic and perioperative statistically significant differences were not observed between the 2 groups. The incidence of PONV in the ramosetron and placebo groups was 46.7% and 51.1%, respectively ( P =0.51). We found significant differences in the severity of PONV between the 24- to 48-hour postoperative periods in both groups (ramosetron group, P =0.04 and placebo group, P =0.03). The use of rescue antiemetics was significantly lower in the ramosetron group than in the placebo group ( P =0.02). Conclusion: After general anesthesia, scheduled injections of ramosetron 12 and 24 hours after SPA-TLH reduced the severity of PONV and the use of rescue antiemetics. Administration of ramosetron can be considered not only immediately after SPA-TLH but also during the first 24-hour recovery period. Trial Registration: ClinicalTrials.gov Identifier: NCT02011659. Competing Interests: Conflict of interest: No potential conflict of interest relevant to this article was reported.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu